Pulsus Group is glad to announce the 2017 conference in the Hematology series, the 10th World Hematology and Oncology Congress. It is going to be held on November 09-10, 2017 at Vienna, Austria.
World Hematology 2017 has been designed with many interesting and informative scientific sessions; it includes all possible aspects of Hematology and Oncology research and runs under the theme of “Exploring Trends in Hematology and Oncology”.
Pulsus Group Inc is a Medical publisher that adheres to stringent peer-review procedure with a view to set an example in promoting standard medical research with integrity. Pulsus Group takes pride in getting the endorsements of prestigious associations and societies like Canadian medical societies. As an ardent supporter of medical publishing, Pulsus Group closely associates with the Canadian and other international medical research associations. It publishes a wide range of medical journals that focus on medical specialties like cardiology, Integrative Medicine, Surgery and Reproductive Medicine. Pulsus group is closely associated with globally renowned academic and research societies like Canadian Society of Plastic Surgeons, Canadian Society for Aesthetic Plastic Surgery, Groupe pour l'Avancementde la Microchirurgie Canada, Canadian Society for Surgery of the Hand.
Track 1: Oncology and Cancers
Oncology is a branch of medicine that involves the prevention, diagnosis and treatment of cancer. Cancer is a class of diseases characterized by uncontrolled cell growth with the potential to spread to all other parts of the body, which leads to formation of lumps or masses of tissue called tumours (cancer prohibits normal blood function by abnormal cell division in the blood stream, only in the case of leukemia). Tumours grow very rapidly and interfere with the digestive, nervous, and circulatory systems and release hormones that fluctuate function of body. Cancer is the major causes of morbidity and mortality worldwide and accounts for nearly 1 of every 4 deaths in US. Some of the tumour cell does not spread all over the body but they grow uncontrollably like benign tumour. Normal or healthy cell controls their growth and when they become unhealthy they destroys by themselves. A medical professional who practices oncology is known as oncologist.
Recommended: Oncology and Cancers conferences
Methods in clinical cancer research; 17-23 June 2017; Zeist, Netherlands: ESMO-ESO Course on Medical Oncology for Medical Students 2017; 13-18 Jul 2017; Valencia, Spain: ESMO Immuno Oncology Congress 2017; 07-10 Dec 2017; Geneva, Switzerland: American Society of Clinical Oncology (ASCO) 2017 Annual Meeting; 2-6 June 2017; Chicago, USA: 2017 BASO~ACS Annual Scientific Conference and NCRI Cancer Conference; 5-8 November 2017; BT Convention Centre, UK: 2nd World Congress on cancer research & therapy; 02-04 Oct 2017; San Diego, USA: International colloquium on cancer research; December 01-02, 2017; Brisbane, Australia: International Conference on Oncology and Cancer Science; 12-14 June 2017; Sydney, Australia: World Cancer Conference (WCC-2017); 29-30 November 2017; Orland, Florida, USA: WCC annual congress 2017; 19-21 May 2017; Barcelona, Spain.
Track 2: Hematology
Hematology, also well known as “haematology” is the branch of medicine that deals with the study, diagnosis, treatment, prevention and also to the extent of control of diseases related to blood. Hematology includes the study of etiology. It involves the treatment of diseases which usually affect the production of blood and its components; it includes blood cells (RBC, WBC, etc…), hemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and also mechanism of coagulation. These kinds of diseases include hemophilia, blood clots, other bleeding disorders and mostly blood cancers such as leukaemia, myeloma, and lymphoma. The laboratory work related with the study of blood is frequently performed by a medical technologist or medical laboratory scientists. The leucocytes are multipotent cells in bone marrow and have life span of 3-4 days where the yellow blood cells are called as thrombocytes which are small and irregular in shape, having life span of 5-9 days they are mostly seen in mammals and help in blood clotting which are in form of fibrin known as thrombosis that lead to heart stroke, blockage of blood in blood mostly in arms and legs. The number of cells in the body can be detected by C.B.C, known as complete blood count and the high and low amount of cells will lead to many diseases.
Decrease of R.B.C in the body leads to anemia which results in weakness, feeling of tired, breathing problem and person will be noticeably pale. Increases of R.B.C in the body causes polycythemia which can be measured through hematocrit level. Hematopoiesis is defined as formation of blood cellular components and these cells are derived from hematopoiesis stem cells.
Recommended: Hematology conferences
European Hematology Association; 22-25 Jun, 2017; Madrid, Spain: 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9-12, 2017; Atlanta, USA: 2017 ASH® Meeting on Hematologic Malignancies; 08-09 September 2017; Tokyo, Japan: Japanese Society of Hematology 79th Annual Meeting 2017 (JSH 2017); 20-22 October 2017; Tokyo, Japan: Cord Blood World Europe Congress 2017; 17-18 May 2017; London, UK: 3rd Annual Haematology Conference 2017; 3 November 2017; Middlesbrough, united kingdom: Conferences and Meetings on Hematology; 08-10 May 2017; Barcelona, Spain: Spanish Society of Hematology and Hemotherapy and Spanish Society of Thrombosis and Haemostasis Joint Congress 2017 (SETH SEEH 2017); 26-28 October 2017; Malaga, Spain.
Track 3: Organ Specific Cancer
Cancer is one among the leading causes of death all over the world. Organ Specific Cancers are cancers named based on the location of cancer in the body organ. There are different types of cancers which effected different organs of the body ,Some of them are Head and Neck Cancer, Brain cancer, Lung cancer, Oral cancer, Liver cancer, Breast cancer, Prostate cancer, Gastric cancer, Pancreatic cancer, Kidney (Renal Cell) cancer, Leukemia and many more. These are different types of cancers that come under category of Organ Specific Cancer. Cancers of the brain are the consequence of abnormal growths of cells in the brain and leads to brain cancer. the most common cancer of the head and neck is Oral squamous cell carcinomas (OSCCs), which accounts for over 300,000 new cancer cases worldwide annually. Hepatocellular carcinoma (HCC) is the sixth most common cancer and third commonest cause of cancer mortality in the world. Lung, prostate, colon, rectum, stomach and liver are the most common sites affected in men by cancer. The most common sites affected by cancer in women are breast, colon, rectum, lung, cervix and stomach.
Recommended: Organ Specific Cancer conferences
IASLC/ESMO European Lung Cancer Conference 2017; 5-8 May 2017; Geneva, Switzerland: The Lung Cancer Centre of Excellence Conference 2017; 3-5 December 2017; Manchester UK: 4th Asia-Pacific Gastroenterology Cancer Summit; 29-30 Apr 2017; Singapore, Singapore: International conference on malignant lymphoma; 14-17 June 2017; Lugarno, Switzerland: Fusion Imaging: Whole - Body and Hybrid Imaging in Oncology; 04-06 May 2017; Heidelberg, Germany: IMCO the 2nd international meeting on cardioncology; 15-16 June 2017, Dan panorama, Israel: New Frontiers in Breast & Thoracic Malignancies; 21-23 Apr 2017; Mumbai, India.
Track 4: Hematooncology and Blood Cancers
Hematologic oncology is the branch of medicine which deals with the study, diagnosis, treatment, and prevention of many diseases related to blood. Haematology involves the study of etiology. It involves the treatment of diseases which usually affect the production of blood and its components; it includes blood cells (RBC, WBC, etc…), haemoglobin, blood proteins, bone marrow, spleen, and also mechanism of coagulation. These kinds of diseases include hemophilia, blood clots, other bleeding disorders and mostly blood cancers such as leukaemia, myeloma, and lymphoma. Blood cancers affect the production of most of the blood cells in the body. These types of cancers start in patient’s bone marrow where the blood is produced. Stem cells mature and develop into three types of blood cells, which are White blood cells, red blood cells or platelets; they are smallest type of blood cell present in the bone marrow. The normal growth of blood cell is stoped by the uncontrolled growth of abnormal blood cells, which are generally cancerous.
Recommended: Hemato-oncology and Blood Cancers conferences
5th International Conference on Advances in Hematology & Oncology; 12-13 August 2017; Idaho, USA: World Conference on Interventional Oncology; 8-11 June 2017; Boston, USA: International Conference on Malignant Lymphoma; 14-17 June 2017; Lugarno, Switzerland: Cancer Metastasis through the Lymphovascular System: Biology & Treatment, 7th International Symposium; 20-22 Apr 2017; San Francisco, USA: 7th. Interamerican oncology conference; 5-6 October, 2017; Buenos Aires, Argentina: MOSM 2017 — Multidisciplinary Oncology Symposium Malaysia 2017; 11-14 May 2017; Subang Jaya, Malaysia.
Track 5: Surgical Oncology
Surgical oncology comes under the field of surgery applied to oncology, which involves the surgical management of tumours, mainly cancerous tumours. The goals of the surgical oncologist are to remove the cancerous cells and keeping an area of healthy tissue surrounding it, also known as a clear margin or clear excision, in order to prevent the cancer from that recurring in that area. Sometimes it is difficult to remove the whole tumor, so therefore a debulking surgery can be done to remove as much as tumour as possible and to relieve symptoms such as pain, airway obstruction, or bleeding. Surgical oncologist are also called as general surgical oncologist, thoracic surgical oncologists, subspecialty of general surgery, gynecologic oncologists experienced in treating the cancer patients. The Ewing Society recognised today as the Society of Surgical Oncology was started by surgeons interested in initiating and promoting the field of oncology. Complex General Surgical Oncology was given by American Board of Surgery, specially ratified as specialty Board certification in the year 2011.
Recommended: Surgical Oncology conferences
Future SSO Annual Cancer Symposia; 21-24 March 2018; Chicago, Illinois: ESSO Course on Surgical Geriatric Oncology; 21-23 September, 2017; Krakow, Poland: ESSO 38; 10-12 October 2018; Budapest, Hungary: Thyroid Ultrasound and FNA Course 2017; May 5 2017; London: 58th Austrian Surgical Congress 2017; 28-30 June 2017; Vienna, Australia: 3rd World Congress on Thyroid Cancer 2017 (WCTC 2017); 27-30 July 2017; Boston, USA: General Surgery 2017; 31 July-3 august 2017; Hilton Head Island, USA: European Society for Trauma and Emergency Surgery 18th Annual Conference 2017 (ESTES 2017); 7-9 May 2017; Bucharest, Romania.
Track 6: Cancer Genomics & Metabolomics
Oncogenomics is a sub-field of genomics that characterizes cancer-associated or cancer related genes. It focuses mainly on genomic, epigenomic and transcript alterations in cancer. The main concept and idea of oncogenomics is to check new group of oncogenes or tumour suppressor genes that may give new areas of research into cancer diagnosis, predicting clinical outcome of cancers and new targets for cancer therapies. The Gleevec, Herceptin and Avastin are the targeted cancer therapies which gave a new way for oncogenomics to elucidate new targets for cancer treatment. Metabolomics is a newly emerging field of 'omics' research and refers to the complete set of small- molecules metabolites, which gives the systematic study of unique chemical fingerprints that leaves cellular processes behind. The metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism that are the end products of cellular processes. Metabolic profiling gives an instantaneous snapshot of the physiology of the given cell. One of the challenging aspects of systems biology and functional genomics is to integrate proteomic, transcriptomic, and metabolomic information which provide a better understanding of cellular biology.
Recommended: Cancer Genomics & Metabolomics conferences
Genome editing and advances in transgenic technology USA congress; 10-11 May 2017; Boston, USA: International conference on genetics and molecular research; 22-24 May 2017; Dubai, UAE: Whole Transcriptome Data Analysis; 6-9 Jun 2017; EMBL Heidelberg, Germany: Bio banking; 14-15 June 2017; London, United Kingdom: 3rd EACR Conference on Cancer Genomics; 25-28 June 2017; Cambridge, UK: Cancer Genomics; 5-8 Nov 2017; EMBL Heidelberg, Germany.
Track 7: Cancer Diagnosis and Treatment
Cancers are recognized because of the appearance of signs or symptoms or through screening. Neither of these leads to exact diagnosis of disease, it mainly requires the examination of a tissue sample by a pathologist. Cancer can be treated by many methods, such as surgery, chemotherapy, hormonal therapy, radiation therapy, targeted therapy and synthetic lethality. People suffering with cancer can be investigated through medical tests. These commonly include blood tests are X-rays, CT scans and endoscopy. The tissue diagnosis from the biopsy indicates the type of cell that proliferates, through its histological grade, genetic abnormalities and other features. Thus all together it gives the useful information about molecular changes such as mutations, fusion genes and numerical chromosome to estimate or show the prognosis and to choose the best treatment. Cytogenetics and immunohistochemistry are other common tissue tests. The removal of the cancer without damaging the other parts of the body (by achieving cure with near-zero adverse effects) is the main goal of treatment. The type of treatment depend on the type of cancer the patient is suffering with and how advanced it is. Some people with cancer have only one type of treatment. But for most of the people, they have a combination of treatments, such as surgery with chemotherapy (use of drugs to kill cancer cells) or radiation therapy. Immunotherapy, targeted therapy, or hormone therapy are other kind of treatment for cancer.
Recommended: Cancer diagnosis and Treatment conferences
Cancer Diagnosis & Therapy Congress; 3-4 September 2015; London, United Kingdom: 24th Asia Pacific Cancer Conference 2017 (APCC 2017); 22-24 June 2017; Seoul, South Korea: ECCO 2017 from evidence to practice in multidisciplinary cancer care; 27-30 January 2017; Amsterdam, Netherlands: Cancer Metastasis through the Lymphovascular System: Biology & Treatment, 7th International Symposium; 20-22 Apr 2017; San Francisco, USA: Integrating science into oncology for a better patient outcome; 08-12 Sep 2017; Madrid, Spain: 2nd World Congress on cancer research & therapy; 02-04 Oct 2017; San Diego, USA.
Track 8: Blood Disorders
Blood is living tissue consists of liquid and solids. The liquid part is known as plasma, which consists of water, salts and protein. The solid part of blood contains red blood cells, white blood cells and platelets. Blood disorders affect one or more parts of the blood which unable it from doing its functions, it can be acute or chronic. Many blood disorders are inherited. Haemophilia A is a genetic deficiency in clotting factor VIII, which increases the bleeding in most of the males. About 70% of the time it is inherited as an X-linked recessive trait, but around 30% of cases raised due to spontaneous mutations. The second-most common form of haemophilia is Hemophilia B is a blood clotting disorder caused by a mutation of the factor IX gene, leading to deficiency in its factor IX. Therefore it is sometimes also known as Christmas disease, named after Stephen Christmas, the first patient known with this name of disease and report of its identification was published in the Christmas edition of the British Medical Journal. Both male and female are effected by haemophilia c. However, it most commonly occurs in Jews of Ashkenazi descent which is also most famously known as fourth coagulation disorder after von Willebrand's disease and haemophilia A and B.
In USA it is thought to affect 1 in 100,000 of the adult population which is 10% as common as haemophilia A. Idiopathic thrombocytopenic purpura (ITP), is defined as isolated low platelet count (thrombocytopenia) with normal bone marrow and absence of other causes of thrombocytopenia. It is also known as immune thrombocytopenia or primary immune thrombocytopenia or primary immune thrombocytopenic purpura or autoimmune thrombocytopenic purpura. The most common disease described in humans is Von Willebrand diseases which is hereditary coagulation abnormality. Platelets also known as "thrombocytes" are blood cells, its function (along with the coagulation factors) is to stop bleeding by clumping and clogging blood vessel injuries. Platelets have no cell nucleus, due to genetic blood disorders.
Recommended: Blood Disorders conferences
ICHBD 2017: 19th International Conference on Hematology and Blood Disorders; 21-22 September 2017; London, United Kingdom: International Conference on Blood Disorders and Haematology 2017; 21-22 Sep 2017; San Francisco, USA: ICHBD 2017: 19th International Conference on Hematology and Blood Disorders; 9-10 October 2017; Osaka, Japan: EHC 2017 Leadership Conference; 29 June-2nd July 2017; Brussels, Belgium: 14th International Symposium on Myelodysplastic Syndrome 2017 (MDS 2017); 3-6 May 2017; Valencia, Spain: 2017 ASH® Meeting on Hematologic Malignancies; 08-09 September 2017; Fairmont Chicago, IL.
Frequently a bone marrow biopsy is done majorly for the diagnosis of the blood disorders. This usually includes a study of the chromosomes (cytogenetics) and an examination of the surface proteins or receptors on the bone marrow cells through the process of flow cytometry. Treatments of blood disorders vary depending on the type of disease, and can include simple observation, use of steroids and other immune-modulating therapies, transfusions or coagulation factor support, growth factor supplementation, complex chemotherapy and bone marrow transplantation. Palliative care is one of the most multidisciplinary approaches to specialised medical care for people with serious illnesses. The spleen is similar to the structure of large lymph node and acts as a blood filter. Anticoagulants (antithrombics) are a class of drugs that work to prevent the coagulation that is clotting of blood. Some anticoagulants are used in medical equipment; they are most commonly like test tubes, blood transfusion bags, and renal dialysis equipment. One type of vascular filter is vena cava, which is a medical device that is implanted by interventional radiologists or vascular surgeons into the inferior vena cava to presumably prevent life-threatening pulmonary emboli therapy with the use of ionizing radiation, generally as part of cancer treatment to manage and control or kill malignant cells. Most of the hematologist uses physical examinations for the treatment of the patient, the patient's medical history and laboratory testing to detect hematological diseases of the patient.
Recommended: Blood Disorders Diagnosis and Treatment conferences
ICHBD 2017: 19th International Conference on Hematology and Blood Disorders; 21-22 September 2017; London, United Kingdom: Acute Leukaemia Forum 2017; 21 April 2017; San Francisco, USA: 17th International Workshop on Chronic Lymphocytic Leukaemia 2017 (iwCLL 2017); 12-15 May 2017; New York City, USA: XVII International Workshop on Chronic Lymphocytic Leukaemia; 12-15 May 2017; New York City, USA.
Track 10: Blood Transplantation
Umbilical cord blood is an alternative source of hematopoietic stem cell for those patients suffering with the hematologic disease and can be cured by allogeneic hematopoietic cell transplantation. The umbilical cord, conduit between the developing embryo or fetus and the placenta. The umbilical vein supplies the fetus nutrient-rich blood from the placenta. The hematopoietic bone marrow transplant, the HSC are removed from the pelvis of the donor, through a big needle that reaches the centre of the bone. Acute myeloid leukemia is another type of cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells (WBC) which accumulates in the bone marrow that interfere with the production of normal blood cells. The formation of a blood clot inside a blood vessel that does not allow the blood to flow through the circulatory system is known as thrombosis. The process of stoppage of bleeding, which is to keep blood within a damaged blood vessel is known as Hemostatic. It is the first stage of wound healing. Metabolic syndrome is one disorder among others as it utilizes energy and stores it, diagnosed or detected by a co-occurrence of three out of five of the following medical conditions, such as obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, low high-density lipoprotein (HDL) levels. Metabolic syndrome gives rise to the risk of developing cardiovascular disease and diabetes. Blood transfusion is usually defines as the process of receiving blood or blood products into one's circulation intravenously and also used for various medical conditions to replace lost components of the blood. Early transfusions uses the whole blood, but modern medical practice commonly uses only components of the blood, like red blood cells, white blood cells, plasma, clotting factors, and platelets.
Recommended: Blood Transplantation conferences
Asia Pacific Blood and Marrow Transplantation Group 22nd Annual Congress 2017 (APBMT 2017); 28-30 October 2017; Tehran: 28th Regional Congress of the ISBT; 25-28 November 2017; Guangzhou, China: 59th ASH Annual Meeting & Exposition; 9-12 December 2017; Atlanta, GA: Visionaries joining cord blood world Europe; 17-18 may 2017; business design centre, London: Clinical and Laboratory Haemostasis 2017 UK NEQAS for Blood Coagulation Annual Scientific Meeting 2017 (CLH 2017); 7 June 2017; Sheffield, England: HAA Annual scientific meeting; 29 Octobe-01 November 2017; Sydney, Australia.
Track 11: Pediatric Hematology and Oncology
Pediatrics also spells and pronounced as paediatrics or pædiatrics, is a branch of medicine which deals with the medical care of infants, children, and adolescents. The age limit usually ranges from birth up to 18-21 years of age (in some places until completion of secondary education). A medical practitioner who specializes in this area is called as a paediatrician or paediatrician. The word pediatrics and its cognates mean "healer of children"; they derive from two Greek words: παá¿–ς (pais "child") and á¼°ατρÏŒς (iatros "doctor, healer"). Pediatricians work both in primary care physicians and hospitals, especially they works in a specialized subfields such as neonatology. Pediatric haematologists or Pediatric oncologists diagnose, treat, and manage children and teens with cancers which include leukaemia, lymphomas, brain tumours, bone tumours, and solid tumors. The hematology oncology of infancy and childhood is a current area of resarch where its development depended upon the evolution of the science of Hematology and on study of the blood and its elements. The body size differences are paralleled by maturation changes. The body of an infant or neonate is substantially physiologically different when compare to an adult. Congenital defects, genetic variance and developmental issues are some greater concern to pediatricians as compare to adult physicians. children, in most jurisdictions and with certain exceptions, can’t make decisions for themselves. The issues of guardianship, privacy, legal responsibility and informed consent and shuld are taken care in every paediatric procedure.
Recommended: Paediatric Hematology and Oncology conferences
2017 ASH® Meeting on Hematologic Malignancies; 08-09 September 2017; Fairmont Chicago, IL: American Society of Paediatric Hematology / Oncology 30th Annual Meeting 2017 (ASPHO 2017); 26-29 April 2017; Montreal, Canada: Neuroscience Update in Paediatric Neuro-Oncology; 22 April 2017; Houston, USA: 28th Annual Meeting of the International BFM Study Group 2017 (IBFM 2017); 10-12 May 2017; Jerusalem, Israel: Paediatric Neuro-Oncology Basic and Translational Research Conference; 15 June 2017 - June 16, 2017; New York, N.Y: SIOP 2017; 12-15 October 2017; Washington, USA.
Track 12: Hematology & Cancer Immunology
Erythrocytes are also known as red blood cells that carry oxygen to the body and collect carbon dioxide from the body through haemoglobin. It has a life span of 120 days, and helps in protecting the healthy cells, as W.B.C (leucocytes) act as the defending cells in the protection of immune system from the foreign cells or antigens. The leucocytes are multipotent cells in bone marrow and have life span of 3-4 days where the yellow blood cells are called as thrombocytes which are small and irregular in shape, having life span of 5-9 days they are mostly seen in mammals and help in blood clotting which are in form of fibrin known as thrombosis that lead to heart stroke, blockage of blood in blood mostly in arms and legs. The number of cells in the body can be detected by C.B.C, known as complete blood count and the high and low amount of cells will lead to many diseases. Decrease of R.B.C in the body these causes of anemia which leads to weakness, feeling of tired, breathing problem and person will be noticeably pale. Cancer immunology is a branch of immunology that deals with the interactions of immune system with cancer cells (also called tumors or malignancies). It is a field of research to innovate cancer immunotherapies to treat and retard progression of the disease. The immune response, having the capacity of recognition of cancer-specific antigens, forms the basis of targeted therapy (like vaccines & antibody therapies) and tumour marker-based diagnostic tests.
Recommended: Hematology & Cancer Immunology conferences
Tumour Immunology and Immunotherapy; 20-23 October 2016; Boston, USA: Cancer, Inflammation and Immunity; 11-13 June 2017; San Diego, Caliph: World Cancer Conference (WCC-2017); 29-30 November 2017; Orland, Florida: 5th International Conference on Advances in Hematology & Oncology; 12-13 August 2017; Idaho, USA: Italian Society of Haematology 2017 (SIE 2017); 15-18 October 2017; Rome: SITC 2017; 8- 12 November 2017; Maryland, USA: 2nd World Congress on cancer research & therapy; 02-04 Oct 2017; San Diego, USA.
Track 13: Biomarkers in Hematology and Oncology
A cancer biomarker refers to a substance or process which indicates the presence of cancer in the body, and are particularly associated with genetic mutations or epigenetic alterations, which determine whether individuals are susceptible to particular types of cancers. Some of the potentially predictive cancer biomarkers include mutations on genes such as KRAS, p53, EGFR, erbB2 for colorectal, esophageal, liver, and pancreatic cancer. Mutations of genes such as BRCA1 and BRCA2 are for breast and ovarian cancer. abnormal methylation of tumour suppressor genes like p16, CDKN2B, and p14ARF are mostly for brain cancer. hypermethylation of MYOD1, CDH1, and CDH13 are for cervical cancer and finally hyper methylation of p16, p14, and RB1, for oral cancer. Therefore these kinds of biomarkers can be assayed in non-invasively collected biofluids like blood or serum.
Recommended: Biomarkers in Hematology and Oncology conferences
9TH World congress of melanoma; 18-21 October 2017; Brisbane, Australia: 2nd annual advances in immuno-oncology congress; 15-16 may 2017; London, UK: 2nd international conference on oncology and radiation; 23-25 October 2017; lass Vegas, USA: Radiation Oncology Conference for Therapists & Dosimetrists; 7-9 September 2017; Niagara Falls, New York: 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9-12, 2017; Atlanta, USA.
Track 14: Cancer Drugs and Vaccines
The main purpose of the drug is not only treating cancer, but also for relieving symptoms of the cancer such as pain and side-effects, such as nausea, commonly seen with the various types of treatment. Vaccines have been developed that prevent infection by some carcinogenic viruses. Human papillomavirus vaccine (Gardasil and Cervarix) decrease the risk of developing cervical cancer and helps in decresase in the risk of cancer. The hepatitis B vaccine prevents infection with hepatitis B virus and thus decreases the risk of liver cancer. The administration of human papillomavirus and hepatitis B vaccinations is advisable most commonly. Some cancer drugs are Cabazitaxel, Capecitabine, Carboplatin, and Cetuximab. Chemotherapy drug combinations are as such Cisplatin, Crizotinib. Most anti-cancer drugs act by inhibiting DNA synthesis in the cell growth cycle, because anti-cancer drugs generally affect rapidly dividing cells, other non-cancerous cells will also be affected. The site of the cells which is affected determines the side-effects of the individual drugs. Other cells affected include blood cells, which fight with the infection, helps in the blood clotting, and carry oxygen to all parts of the body. The movement the blood cells are affected, patients are more likely to get infected they may bleed very easily, and may feel weak and very tire. Rapidly dividing cells in hair roots, and cells that line the digestive tract, may also be affected.
Recommended: Cancer Drugs and Vaccines conferences
Immuno-Oncology Summit 2017; 28 Aug-01 Sep 2017; Boston, USA: Innovation and Biomarkers in Cancer Drug Development; 8 - 9 September 2017; Brussels, Belgium: The world vaccine congress Europe 2017; 10-12 October 2017; BARCELONA, Spain: Global experts meeting in pharmaceutics and drug delivery system; 12-13 October 2017; Osaka, japan: 11th International Conference on Immunopharmacology and Immunotoxicology; 20-21 Nov 2017; Melbourne, Australia: 12th Annual Drug Discovery Chemistry; 23-27 Apr 2017; San Diego, USA.
Track 15: Hematology & Oncology Nursing
Hematology nurses are specially trained to provide nursing care for patients those who are suffering from blood diseases or disorders. They also take the atmost care in assisting or handling with blood transfusions, blood tests, research and chemotherapy. Some of the more commonly-known blood diseases and disorders include: leukemia, lymphoma, sickle cell anaemia and haemophilia. Hematology nurses initiate a plan of care to manage symptoms that result from such blood problems. Hematology nursing are also more commonly similar to oncology nursing, they help patients with pain management if their cancer is particularly aggressive or out of reach. Hematology nurses may work with adults only in specialized working areas. Their responsibilities of these nurses include: taking medical histories and performing examinations or blood analysis, starting IVs and working with physicians to diagnose various blood diseases and disorders. Hematology nurses are back bone for their patients and their families as they teach them how to fight with the diseases and help them in manage their blood disease. Advanced practice hematology nurses have some prescriptive authority and can also order diagnostic lab work done.
The oncology nurse works as a coordinator of care i.e., they take the atmost care of an individual, collaborating with other cancer care providers and team members to provide required care that the individual need. Thus the advance nursing practice in oncology leads to mastery of the nursing process which provides the ability to guide, and evaluate nursing practice delivered to individuals diagnosed with cancer. The oncology nurse works expertly with the multidisciplinary oncology team to achieve realistic healthcare goals for an individual or for an entire community.
Recommended: Hematology & Oncology nursing conferences
19th Annual oncology nursing conference; 18-Nov-17; Huron eve, Chicago: 5th International Conference on Advances in Hematology & Oncology; 12-13 August 2017; Coeur d’Alene Resort Coeur d’Alene, Idaho: Oncology nurse advisor navigation summit; 15-17 June 2017; Austin, TX: AONN academy of oncology nurse & patient annual conference; 16-19 November 2017; Orland, Florida: 41st Annual Conference & Exhibit; 17-19 August 2017; Palm Springs, USA: 27th Annual Mayo Clinic Hematology/Oncology Reviews 2017; 17-19 August 2017; Fernandina Beach, USA: 1st Annual School of Nursing Oncology; 4-5 August 2017; Nashville, USA.
Track 16: Cancer Pharma Industry
Cancer is one of the greatest health challenges, and a leading cause of death in every corner of the world. The global market for Hematologic drugs is predicted to grow twice as fast as that of other pharmaceuticals over the next five years. Top companies include Janssen biotech, Takeda oncology, Boehringer ingelheim, Roche, Novartis, Celgene, Johnson & Johnson, Amgen. The Pharma industry embraces hematology in producing various Biological Drugs and Generic Drugs with Increasing Investments, Healthcare Expenditures and growth in Cancer Pharmaceutical Companies. The cancer industry is the most commonly valuable business in the USA. It has been noticed that, there are 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US in the year 2014. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research mainly as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with the rise of 39 percent to $173 billion by the upcoming year that is 2020. The most common moto of the cancer industry is it employs too many people and produces too much income to allow a cure to be found.
Recommended: Cancer pharma industry conferences
International Biotechnology and pharmaceutical Industry Forum; 11-13December 2017; New Delhi, India: World Summit on Cancer Science and Therapy; January 23rd-25th, 2017; Singapore: 2nd World Congress on Cancer Research & Therapy; 02-04 Oct 2017; San Diego, USA: Methods in clinical cancer research; 17-23 June 2017; Zeist, Netherlands: International colloquium on cancer research; December 01-02, 2017; Brisbane, Australia: World Cancer Conference (WCC-2017); 29-30 November 2017; Orland, Florida, USA.
Track 17: Diagnostic and Equipment Market
The major driving factors for hematology and oncology diagnostics market include, increasing incidences of blood related disorders. Approximately 9.8% of the population in U.S. was diagnosed with leukemia, which was started by Leukemia & Lymphoma Society (LLS). About 1,658,370 new cases of cancer in 2015 were found due to myeloma and lymphoma. Based on the type of product, global hematology diagnostics market is divided into hematology analysers market and hematology reagents market. Hematology analysers perform complete blood picture, coagulation or erythrocyte sedimentation rates tests. In recent years, the use of hematology diagnostics market has increased due to technological advancements, and rising demand for improved healthcare facilities. Introduction of digital imaging systems in hematology and oncology laboratories and growing use of microfluidics technology in hematology analysers is another best approach for growth of the global hematology diagnostics market. Clinical Hematology laboratories are primarily focused on measuring whole blood components such as white blood cells, red blood cells, and platelets, as well as the level of hemoglobin in the blood.
Recommended: Diagnostic and Equipment Market conferences
World Summit on Cancer Science and Therapy; 23-25 January 2017; Singapore: International Biotechnology and pharmaceutical Industry Forum; 11-13 December 2017; New Delhi, India: Cancer Imaging and Therapy; 02-06 Apr 2018; Diplomat Beach Resort, Florida USA: Cancer Diagnosis & Therapy Congress; 3-4 September 2015; London, United Kingdom: 24th Asia Pacific Cancer Conference 2017 (APCC 2017); 22-24 June 2017; Seoul, South Korea.
Track 18: Hematology & Oncology: Case Reports
Case reports of hemotology or oncology gives the information of the preventive or therapeutic interventions, as these generally require stronger evidence. Thus a case report is an enlarged report of all the details of a disease or of a disorder usually made for an individual patient usually logged in medical field. Case reports give the demographic profile of the patient suffering from disease, but stereotypically reference any unusual or unique incidences. In this hematology based conference, various special cases where treatment was undiscovered or a special case which might lead the insights into the hematology research are discussed. Thus a case report of hematology and oncology is a unique therapeutic approach.
Recommended: Hematology and oncology: case reports conferences
ESMO-ESO Course on Medical Oncology for Medical Students 2017; 13-18 Jul 2017; Valencia, Spain: European Hematology Association; 22-25 Jun, 2017; Madrid, Spain: 2017 ASH® Meeting on Hematologic Malignancies; 08-09 September 2017; Tokyo, Japan: International Conference on Oncology and Cancer Science; 12-14 June 2017; Sydney, Australia: 5th International Conference on Advances in Hematology & Oncology; 12-13 August 2017; Idaho, USA: World Conference on Interventional Oncology; 8-11 June 2017; Boston, USA.
Track 19: Entrepreneurs Investment Meet
Now a day’s several biotech and pharmaceutical industries are emerging. Each of them partially or completely relate to the hematology. Many research teams are found all over the world to work on hematology and clinical and experimental hematology. Large scale production of diagnostics and drugs is fashioned now to meet the needs of the increasing demand as the expanded research field suggests.
Pulsus Group is glad to announce the 2017 conference in the Hematology series, the 9th International Conference on Clinical and Experimental Hematology. It is going to be held on October 16-17, 2017 at Rome, Italy.
Clinical Hematology 2017 will be organized around the theme “Breakthroughs and setbacks in Clinical and Experimental Hematology”.
Clinical Hematology 2017 is comprised of many interactive scientific sessions on different types of Blood disorders as well as various diagnostic and therapeutic advancements in this field. It is an initiative to unite the diverse research and business communities working in this field under a one roof to explore every single aspect of Hematology and Blood Diseases. Clinical Hematology 2017 welcomes the hematologists, immunologists, pathologists, oncologists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of it in Hematology conferences.
According to market study, market value of Hematology at present is $15.13 billion. A major part of research is going on at the top Universities across the globe, on Hematology conference and the grants allotted for this research field is around $10.54 billion. Many companies are associated with the blood testing equipment along with various diagnostic instruments, hematologic drugs and other therapeutics, the revenue generated is around $21.1 billion on average by this companies. Besides this various societies and research labs are also associated in this research field.
Clinical Hematology 2017 will provide an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster and Live Streaming, B2B and Scientific Meetings.
Why to attend?
Clinical Hematology 2017 will provide a stimulating scientific environment and a platform for the participants to exchange ideas, establish research collaboration and networking by attending the Hematology conferences. It will be amazing opportunity for the attendees to explore the beautiful city with gaining knowledge, sure to raise insights, conflate present with future and cogitate on ideas and reality in Hematology meetings. To fight against these hard to cure blood diseases, Clinical Hematology 2017 has taken this initiative to explore every aspects of Hematology research.
Hematology is a branch of biology that includes various research areas such as pathology, internal medicine, clinical laboratory, physiology, immunology and pediatrics. This conference will witness a collection of various arenas in Hematology and as it involves a vast range of medical streams within it. This conference will be an excellent platform for interdisciplinary interactions, to exchange and share knowledge under a single roof.
The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Clinical Hematology 2017, where you will be sure to have a meaningful experience with scholars from around the world.
Importance & Scope:
Clinical Hematology 2017 offers the best platform for the experts, researchers, students and business delegates with its well organized scientific program covering every minute detail about the clinical and experimental aspects on hematology and blood diseases, from the basic causes behind blood diseases to the latest trends in diagnostic and treatment of blood diseases. This international event is an effort to find a weapon against chronic disorders like blood cancer, Sickle cell anemia, hemophilia, lymphoma and myeloma and to discuss the role of Immunoglobulin in blood, antibody and antigen reactions, the red blood cell and the immunological properties of blood which gives a better insight about the associated causes and disease portfolio.
Pulsus Group Inc welcomes all the hematologists, immunologists, pathologists, oncologists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of the esteemed Clinical Hematology 2017. Advanced Diagnostic and therapeutic equipment along with the novel drugs for the blood diseases are an integral part of the Hematology research, hence it will be an excellent amalgamation of academia and industry as it involves every aspects of empirical and conceptual thinking in exploring new dimensions in this field. It is open to all types of research methodologies both from academia and industry.
Conference Highlights :
Glance at Market of Hematology :
According to market study, the total market value of Hematology at present is $15.13 billion. The hematology products segment holds the largest share of the hematology market in 2016. The market value is analysed by 2 segments, namely, hematology reagents and hematology instruments. These two segments had a positive growth till 2013, with a total market value of $4.3 billion, covering $0.6 billion for instruments and $3.6 billion for reagents, and growing at a CAGR of 7.3%. The global market of hematology instruments and reagents, by 2019, is expected to reach $3.13 billion, at CAGR of 5.2% from 2014 to 2019.
The global hematology market is divided into hematology products & services. Hematology products market has been segmented into instruments and consumables. The hematology instruments market is further segmented into analyzers and slide strainers/makers. Whereas, the hematology consumables market has been classified into three major segments namely; regents, stains, and controls and calibrators. Furthermore, based on the end-users, the global hematology market has been segmented into commercial organizations, stand-alone hospitals, research institutes, and clinical testing labs.
The Centers for Medicare & Medicaid Services (CMS) has estimated that the healthcare spending in the U.S. is expected to grow from $2.7 trillion in 2011 to about $4.6 trillion in 2018, at a CAGR of 6.8% for the same period. Europe holds the second largest market. Similarly, in emerging countries, the growing awareness and an increasing middle-class population, with more disposable incomes to spend on healthcare, are the driving factors for the growth of coagulation market.
It is also expected to grow at the highest growth rate by next five years, owing to the increasing development of new hematology reagents. In addition, based on the end-users, the global hematology market has been segmented into commercial organizations, stand-alone hospitals, research institutes, and clinical testing labs. The clinical testing labs hold the largest share of the hematology market in 2017.
A major part of research is going on at the top Universities across the globe, the grants allotted for this research field is around $10.54 billion. Many companies are associated with the blood testing equipment along with various diagnostic instruments, hematologic drugs and other therapeutics, the revenue generated is around $21.1 billion on average by this companies. Besides this various societies and research labs are also associated in this research field.